Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Epirubicin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    181 result(s) found for: Epirubicin. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-001263-22 Sponsor Protocol Number: YMB1002-02 Start Date*: 2005-01-07
    Sponsor Name:YM Biosciences Inc
    Full Title: A Phase III study of DPPE (Temilifene) combined with Epirubicin and Cyclophosphamide versus Epirubicin and Cyclophosphamide alone as First – line Treatment in Metastatic/Recurrent Cancer
    Medical condition: Metastatic and/or recurrent cancer of the breast
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001648-79 Sponsor Protocol Number: KFE13.10 Start Date*: 2013-07-22
    Sponsor Name:Odense University Hospital
    Full Title: Epirubicin as 2nd line treatment to patients with TOP2A gene amplified and oxaliplatin refractory metastatic colerectal cancer
    Medical condition: TOP2A gene amplified and oxaliplatin refractory metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-004126-56 Sponsor Protocol Number: NUTH-2005-03523 Start Date*: 2006-03-07
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust
    Full Title: Observational pharmacokinetic study of doxorubicin and cyclophosphamide in patients with early breast cancer.
    Medical condition: Early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003723-21 Sponsor Protocol Number: BSMO-2014-01 Start Date*: 2015-05-27
    Sponsor Name:Belgian Society of Medical Oncology
    Full Title: A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple ne...
    Medical condition: Stage II and III triple negative breast cancer patients suitable for preoperative chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002030-19 Sponsor Protocol Number: ABCSG-24 Start Date*: 2005-02-22
    Sponsor Name:AUSTRIAN BREAST CANCER STUDY GROUP
    Full Title: A randomized phase III study comparing epirubicin, docetaxel and capecitabine + G-CSF to epirubicin and docetaxel + G-CSF as neoadjuvant treatment for early HER-2 negative breast cancer and compari...
    Medical condition: early HER-2 breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002469-37 Sponsor Protocol Number: CA209-7FL Start Date*: 2020-01-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With Hi...
    Medical condition: Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) FR (Completed) PL (Completed) NL (Completed) BE (Completed) DK (Completed) FI (Completed) IE (Completed) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-003695-47 Sponsor Protocol Number: WO39391 Start Date*: 2018-07-24
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN...
    Medical condition: Triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Prematurely Ended) CZ (Completed) ES (Temporarily Halted) HU (Prematurely Ended) DK (Completed) AT (Prematurely Ended) BE (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011113-25 Sponsor Protocol Number: SA2009 Start Date*: 2009-05-29
    Sponsor Name:Per Honore
    Full Title: Populationsbaseret farmakokinetisk og farmakodynamisk doseringsmodel af epirubicin, cyklofosfamid og docetaxel til brystkræft
    Medical condition: brystcancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002300-12 Sponsor Protocol Number: EPOS_ZKSJ0134 Start Date*: 2021-12-20
    Sponsor Name:Friedrich Schiller University
    Full Title: Epirubicin for the Treatment of Sepsis & Septic Shock
    Medical condition: Patients with sepsis or septic shock, currently hospitalized at the Intensive Care Unit (ICU) or Intermediate Care (IMC) regardless where the sepsis was first diagnosed.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000967-24 Sponsor Protocol Number: HED-324-PAE-0090-I Start Date*: 2005-12-30
    Sponsor Name:Technical University of Munich
    Full Title: Evaluation of Response Rate to Pre-operative Docetaxel + Herceptin study part A and Docetaxel study part B In Locally Advanced Breast Cancer Patients, Stratified by HER2-Status, Trial Phase II
    Medical condition: therapeutic principles of primary systemic (=neo adjuvant) chemotherapy. In addition to the increased number of breast conserving operations, that could be already achieved by partially remission,...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003126-15 Sponsor Protocol Number: DBCG 07-READ Start Date*: 2008-05-06
    Sponsor Name:DBCG
    Full Title: Randomized trial of sequential epirubicin and docetaxel against docetaxel in patients with early operable breast cancer.
    Medical condition: Women with operable breast cancer and increased risk of recurrence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018754-13 Sponsor Protocol Number: FLOT4 Start Date*: Information not available in EudraCT
    Sponsor Name:Krankenhaus Nordwest GmbH
    Full Title: A randomized multicenter Phase II/III Study comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) versus Epirubicin, Cisplatin and 5-FU (ECF) in patients with locally advanced resectable ad...
    Medical condition: locally advanced resectable adenocarcinoma of the esophagogastreal junction or the stomach
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000490-21 Sponsor Protocol Number: SUCCESS Start Date*: 2005-08-24
    Sponsor Name:1. Frauenklinik der LMU- Innenstadt
    Full Title: Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial SUCCESS-Trial
    Medical condition: This is an open-label, multicenter, 2x2 factorial design, randomized controlled, Phase III study comparing the time to recurrence after randomisation in patients with early primary breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003582-16 Sponsor Protocol Number: dense get 2005 Start Date*: 2006-07-11
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Dose-dense treatment with gemcitabine, epirubicin and paclitaxel GET combination in advanced breast cancer a phase II parallel study
    Medical condition: Women with advanced metastatic breast cancer, not previously treated with anthracyclines or taxanes
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006292 HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005002-30 Sponsor Protocol Number: ICORG09-13 Start Date*: 2012-01-05
    Sponsor Name:ICORG-the All Ireland co-operative Oncology Research group
    Full Title: Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer.
    Medical condition: Metastatic breast cancer in patients who are HER-2-positive and Topoisomerase II alpha positive.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001226-25 Sponsor Protocol Number: HD-TNBC-TRIAL Start Date*: 2015-04-20
    Sponsor Name:ISTITUTI OSPITALIERI DI CREMONA
    Full Title: A phase II randomized, open-label neo-adjuvant study of standard chemotherapy regimen compared to high dose chemotherapy regimen with autologous stem cell transplantation in patients with triple ne...
    Medical condition: Triple Negative Breast Cancer patients with breast tumor >2,5 cm
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002061-12 Sponsor Protocol Number: SBG2004-1/ABCSG25/GBG53 Start Date*: 2007-08-17
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: PANTHER (The SBG 2004-1/ABCSG 25/GBG53 Protocol) - a randomised phase III study: Comparing two weekly and tailored epirubicin + cyclophosphamide followed by two weekly tailored docetaxel (dtEC->dtT...
    Medical condition: lymph node positive breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed) FI (Prematurely Ended) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001094-16 Sponsor Protocol Number: PROACT Start Date*: 2017-08-08
    Sponsor Name:South Tees NHS Foundation Trust
    Full Title: Preventing cardiac damage in patients treated for breast cancer and lymphoma: a phase 3 Randomised, Open label, blinded endpoint, trial of enalapril to prevent Anthracycline-induced CardioToxicity ...
    Medical condition: Prevention of cardiotoxicity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10048610 Cardiotoxicity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-000657-35 Sponsor Protocol Number: CUP ONE Start Date*: 2008-10-08
    Sponsor Name:Greater Glasgow and Clyde Health Board (GGCHB)/University of Glasgow
    Full Title: A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine incorporating the prospective validation of molecular classifiers and exploratory metabonomics.
    Medical condition: Metastatic Carcinomas of Unknown Primary origin (CUP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013029-41 Sponsor Protocol Number: PACT-13 Start Date*: 2009-07-07
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Proteomic profile analysis to classify advanced pancreatic adenocarcinoma patients for clinical outcome after treatment with PDXG (cisplatin, docetaxel, capecitabine, gemcitabine) or PEXG (cisplati...
    Medical condition: patients affected by adenocarcinoma at stage III or IV who are candidate to receive upfront chemotherapy according to PDXG or PEXG regimen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052747 Adenocarcinoma pancreas LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 21:00:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA